GSK 1795091Alternative Names: GSK1795091
Latest Information Update: 21 Jun 2016
At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics
- Mechanism of Action Immunomodulators; Toll-like receptor 4 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Jun 2016 Preclinical trials in Cancer in United Kingdom (IV) before June 2016
- 09 Jun 2016 GlaxoSmithKline plans a first-in-human phase I trial in Healthy volunteers in USA (IV) (NCT02798978)